NMIN
EVENTS
Developing Genetic Drugs
using nucleic acids & LNPs
IDT Symposium | February 6, 2020
NMIN
About
With the recent release of the first lipid nanoparticle (LNP)/nuclceic acid drug ONPATTRO®, the promise of developing genetic drugs for additional targets has been reignited. LNP delivery tools can enable delivery of functionalized nucleic acid payloads to a variety of tissue types and organisms.
In this event, organized by Integrated Data Technologies together with NMIN, NanoCore and the BC Regenerative Medicine Network (BCRegMed), leading experts will provide an overview of LNP and functional genomics tools, followed by a series of talks on specific applications in this exciting new field.
The event also features a three-minute research proposal competition for trainees, in which trainees will present, in three minutes, a novel or “proof or principle” experiment utilizing these combined technologies that could move forward a particular problem in their field of research or create a tool that would be useful to others.
If you are interested in personalized medicine and the development of precision health tools, this event will be useful to you.
Note that IDT is also offering “Office Hours” with IDT R&D staff on Friday February 7th in the morning, at the BRC library. If you would like some one-on-one time with an IDT research scientist about a particular issue, sign up for a 30-minute timeslot on the registration page.
Organizer:
Dr. Urs Häfeli, PhD, Professor of Pharmaceutical Sciences at the University of British Colombia
NMIN
competition
Graduate students, trainees and post-doctoral fellows are invited to participate in a 3-Minute Research Proposal Competition.
Competitors are challenged to devise a novel or “proof or principle” experiment utilizing these combined technologies (nucleic acid/LNPs) that could move forward a particular problem in their field of research or create a tool that would be useful to others. The experiments should be focused on a proof of principle that could scale to bigger things.
At the event, each competitor will be given three minutes to present, concisely and in clear language, his or her research proposal.
To participate, send a brief abstract of 100-500 words to Bob Setter (rsetter@idtdna.com) at Integrated DNA Technologies by February 3, 2020, at the latest.
The deadline for the submission of abstracts to this event has passed.
A program of talks and a poster competition featuring 46 entries has been generated from the abstracts submitted.
Click the button below to see the list of authors and titles in the poster competition.
Late abstracts will be accepted for consideration as posters.
Please send your late abstract submission as a single-page PDF to:
DEADLINE: FEBRUARY 3, 2020
NMIN
REGISTRATION
Registration to this symposium is free.
However, your advance registration is required for planning purposes.
Note that IDT is also offering “Office Hours” with IDT R&D staff on Friday February 7th in the morning, at the BRC library. If you would like some one-on-one time with an IDT research scientist about a particular issue, sign up for a 30-minute timeslot on the registration page.
We look forward to seeing you on February 6, 2020!
There is no registration fee for this event, but registration is required.
Please register by September 4, 2019
NMIN
Venue
UBC Biomedical Research Centre
Main Conference Room
2222 Health Sciences Mall
University of British Columbia
Vancouver, BC
NMIN
ORGANIZERS
We invite organizations that share NMIN and UBC’s enthusiasm for the enormous potential of nanomedicines to become the dominant medicines of the future, to consider partnering with us as event sponsors.
We offer various levels of sponsorship to ensure the best fit with your organization’s marketing, outreach and networking objectives.
Please review the sponsorship opportunities in our prospectus.
If you are interested in sponsoring, or have any questions, please contact:
Dr. Urs Hafeli
NanoMedicine Day organizer
Professor of Pharmaceutical Sciences, The University of British Columbia
Integrated DNA Technologies, Inc. (IDT) develops and manufactures nucleic acid products that support the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development.
The BC Regenerative Medicine Network advances cellular and regenerative therapies through collaborative, innovative science.
The NanoMedicines Innovation Network is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NancoCore is the Translational nanomedicines Formulation & Characterization Core Facility, which aims to develop high-quality, state-of-the-art lipid nanoparticles encapsulating nucleic acid, small molecule, or peptide drugs that enable proof-of-concept (POC) animal studies.